Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium nucleinate is an immunomodulating agent composed of the sodium salt of nucleic acids, typically extracted from yeast (*Saccharomyces cerevisiae*). It functions primarily as a stimulant of leukopoiesis and an enhancer of both innate and adaptive immune responses. The drug promotes the migration of hematopoietic stem cells from the bone marrow into the bloodstream, accelerates the maturation and activity of T and B lymphocytes, and increases the phagocytic capacity of macrophages. Additionally, it acts as an inducer of endogenous interferon production. Sodium nucleinate is widely utilized in Eastern European clinical practice for the treatment of leukopenia (often induced by chemotherapy or radiation), as well as an adjuvant therapy for chronic infections such as tuberculosis, pneumonia, and various immunodeficiency states.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium nucleinate (Biosintez).